Journal
JOURNAL OF NANOBIOTECHNOLOGY
Volume 20, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12951-022-01524-4
Keywords
Alzheimer's disease; Nanotheranostics; Magnetic resonance imaging; Curcumin; NLRP3 inflammasome
Funding
- National Natural Science Foundation of China [81870836, 82171178, 82101271]
- Natural Science Foundation of Guangdong Province of China [2020A1515110317, 2021A1515010705, 2020A1515010210]
Ask authors/readers for more resources
This study developed a nanotheranostics platform and demonstrated its effectiveness in reducing beta-amyloid plaque burden and improving memory deficits in APP/PS1 transgenic mice. The nanomaterial allowed noninvasive detection by magnetic resonance imaging and quantification of plaque volumes based on three-dimensional analysis.
Background: Alzheimer's disease (AD) is the most common neurodegenerative disorder without effective therapy and lack diagnosis strategy for preclinical AD patients. There is an urgent need for development of both early diagnosis and therapeutic intervention of AD. Results: Herein, we developed a nanotheranostics platform consisting of Curcumin (Cur), an anti-inflammatory molecule, and superparamagnetic iron oxide (SPIO) nanoparticles encapsulated by diblock 1,2-dio-leoyl-sn-glycero-3-phosphoethanolamine-n-[poly(ethylene glycol)] (DSPE-PEG) that are modified with CRT and QSH peptides on its surface. Furthermore, we demonstrated that this multifunctional nanomaterial efficiently reduced beta-amyloid plaque burden specifically in APP/PS1 transgenic mice, with the process noninvasively detected by magnetic resonance imaging (MRI) and the two-dimensional MRI images were computed into three-dimension (3D) plot. Our data demonstrated highly sensitive in vivo detection of beta-amyloid plaques which more closely revealed real deposition of A beta than previously reported and we quantified the volumes of plaques for the first time based on 3D plot. In addition, memory deficits of the mice were significantly rescued, probably related to inhibition of NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasomes. Conclusions: Gathered data demonstrated that this theranostic platform may have both early diagnostic and therapeutic potential in AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available